Joel Greenblatt’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-139,526
| Closed | -$2.02M | – | 1838 |
|
|
2026
Q1 | $2.02M | Sell |
139,526
-25
| -0% | -$358 | 0.01% | 1108 |
|
|
2025
Q4 | $1.99M | Buy |
139,551
+1,028
| +0.7% | +$10.1K | 0.01% | 1044 |
|
|
2025
Q3 | $1.09M | Buy |
138,523
+1,987
| +1% | +$14.1K | ﹤0.01% | 1173 |
|
|
2025
Q2 | $782K | Buy |
136,536
+82,546
| +153% | +$533K | ﹤0.01% | 1204 |
|
|
2025
Q1 | $441K | Buy |
+53,990
| New | +$500K | ﹤0.01% | 1272 |
|
|
2023
Q4 | – | Sell |
-10,606
| Closed | -$129K | – | 1368 |
|
|
2023
Q3 | $129K | Sell |
10,606
-5,652
| -35% | -$72.9K | ﹤0.01% | 1275 |
|
|
2023
Q2 | $204K | Sell |
16,258
-20,242
| -55% | -$240K | ﹤0.01% | 1230 |
|
|
2023
Q1 | $405K | Buy |
36,500
+18,466
| +102% | +$228K | 0.01% | 1033 |
|
|
2022
Q4 | $220K | Buy |
+18,034
| New | +$203K | 0.01% | 1111 |
|
|
2022
Q3 | – | Sell |
-11,561
| Closed | -$124K | – | 1201 |
|
|
2022
Q2 | $124K | Buy |
+11,561
| New | +$95.2K | ﹤0.01% | 1070 |
|
|
2022
Q1 | – | Sell |
-26,356
| Closed | -$304K | – | 1167 |
|
|
2021
Q4 | $304K | Buy |
26,356
+9,537
| +57% | +$106K | 0.01% | 942 |
|
|
2021
Q3 | $161K | Buy |
+16,819
| New | +$172K | 0.01% | 986 |
|
|
2019
Q2 | – | Sell |
-11,047
| Closed | -$150K | – | 1188 |
|
|
2019
Q1 | $150K | Buy |
+11,047
| New | +$135K | ﹤0.01% | 1125 |
|
|
2017
Q3 | – | Sell |
-30,628
| Closed | -$308K | – | 953 |
|
|
2017
Q2 | $308K | Buy |
+30,628
| New | +$246K | ﹤0.01% | 825 |
|
Other funds holding FOLD
Joel Greenblatt's FOLD Position: Q2 2026 in Review
Joel Greenblatt sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 139,526 shares — an estimated $2.02M sold.
Joel Greenblatt first reported a position in FOLD in Q2 2017 and held it in 14 quarters. The position peaked at $2.02M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Joel Greenblatt reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Joel Greenblatt sold 139,526 Amicus Therapeutics shares in Q2 2026, an estimated $2.02M.
- Joel Greenblatt first reported a position in Amicus Therapeutics in Q2 2017 and held it in 14 quarters.
- Joel Greenblatt's Amicus Therapeutics position peaked at $2.02M in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.